B-Cell Non-Hodgkin Lymphoma clinical trials in Pennsylvania
15 active B-Cell Non-Hodgkin Lymphoma trials with a site in Pennsylvania. Describe your situation to see which ones look like a fit.
- SynKIR-310 for Relapsed/Refractory B-NHL
- CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)
- TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- DALY II USA/ MB-CART2019.1 for DLBCL
- A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- CD45BE-HSPC + CART-45 Cells
- A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
- Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies
- Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy
- Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Long-Term Follow-up Study
- CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
- A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
- A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma
- A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
Guides for people searching for a trial
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.